ACCORD-12

Regimen

Experimental
CAPOX-50: radiotherapy 50 Gy + capecitabine + oxaliplatin 50 mg/m² weekly
Control
CAP-45: radiotherapy 45 Gy + capecitabine alone

Population

T3–4 M0 locally advanced rectal cancer (N=598); evaluating intensification of CRT with oxaliplatin.

Key finding

NEGATIVE for primary endpoint: ypCR 13.9% (Cap 45) vs 19.2% (Capox 50), P=.09. Grade 3-4 toxicity 1% vs 25% (P<.001). Near-complete response rates showed numerical improvement with Capox but not significant for primary endpoint; toxicity significantly higher with oxaliplatin addition. Oxaliplatin should not be added to concurrent CRT.

Source: PMID 20194850

Timeline

    Guideline citations

    • NCCN Colon (p.58)
    • NCCN Rectal (p.57)